News
Current Report No. 24/2023 – Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date prepared: 12/22/2023, 10:59 a.m. In relation to the information provided in the periodical reports and, among others, in the recent periodical report for 3Q2023, regarding the planned marketing of new generic drugs in the area of cardiology in 2024, whichRead more »
Current report No. 25/2023- Information concerning preliminary results of the phase 2a clinical trial on CPL’280 in treatment of type 2 diabetes
Subject: Information concerning preliminary results of the phase 2a clinical trial on CPL’280 in treatment of type 2 diabetesLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date: 27.12.2023, 17:19 Content of the report: In relation to current report no. 3/2022 of January 21, 2022 concerning the commencement of aRead more »
Current report No. 23/2023 – Correction of the Periodical Report
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information The Management Board of Celon Pharma S.A. (“Company”) hereby informs that in the “Half-Year Condensed Financial Statements for the 6-month period ended June 30, 2023” published by the Company on 20 September 2023, there was, forRead more »
Current report No. 22/2023 – Signing of an agreement for the implementation and co-funding of Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependent solid tumors
Date prepared: 07/25/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Signing of an agreement for the implementation and co-funding of Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependent solid tumors Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Content ofRead more »
Current report No. 21/2023 – Receipt of a notification regarding a change in the total number of votes in the Company
Date prepared: 07/25/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Receipt of a notification regarding a change in the total number of votes in the Company Legal basis: Article 70 point 1 of the Act on Public Offering – acquisition or disposal of a significant block of shares Content of the report: TheRead more »
Current report No. 20/2023 – Change in the composition of the Management Board of Celon Pharma S.A.
Date prepared: 07/04/2023Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Change in the composition of the Management Board of Celon Pharma S.A.Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report:The Management Board of Celon Pharma S.A. the “Company” hereby informs that onRead more »
Current report No. 19/2023 – Appointment of existing members of the Company’s Supervisory Board for another term
Date prepared: 06/23/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Appointment of existing members of the Company’s Supervisory Board for another term Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (“Company”)Read more »
Current report No. 17/2023 K – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 – correction
Date prepared: June 27, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 – correction Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: InRead more »
Current report No. 18/2023 – List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of Celon Pharma S.A. held on June 22, 2023
Date prepared: June 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of Celon Pharma S.A. held on June 22, 2022 Legal basis subs. 70 point 3 of the Act on Public Offering – General Shareholder’s Meeting, theRead more »
Current report No. 17/2023 – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023
Date prepared: July 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023. Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: The Management BoardRead more »